Fulcrum Therapeutics, Inc. financial data

Symbol
FULC on Nasdaq
Industry
Pharmaceutical Preparations
Location
26 Landsdowne Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.08K % +8.39%
Debt-to-equity 7.98 % -11.3%
Return On Equity -3.94 % +89.3%
Return On Assets -3.65 % +89.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54M shares -13.2%
Common Stock, Shares, Outstanding 54M shares -12.8%
Entity Public Float 309B USD +88.7%
Common Stock, Value, Issued 54K USD -12.9%
Weighted Average Number of Shares Outstanding, Basic 62K shares +1.1%
Weighted Average Number of Shares Outstanding, Diluted 62K shares +1.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 63.4M USD -11.7%
General and Administrative Expense 36.4M USD -12.5%
Operating Income (Loss) -21.9M USD +80.2%
Net Income (Loss) Attributable to Parent -9.73M USD +90%
Earnings Per Share, Basic -0.16 USD/shares +89.9%
Earnings Per Share, Diluted -0.16 USD/shares +89.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 58.2M USD +128%
Assets, Current 250M USD +3.19%
Property, Plant and Equipment, Net 3.9M USD -25.2%
Operating Lease, Right-of-Use Asset 5.68M USD -20.8%
Other Assets, Noncurrent 10K USD -99.5%
Assets 261M USD +1.17%
Accounts Payable, Current 1.16M USD -57.8%
Employee-related Liabilities, Current 2.99M USD -36.6%
Liabilities, Current 11M USD -19.2%
Operating Lease, Liability, Noncurrent 6.44M USD -25.3%
Other Liabilities, Noncurrent 197K USD 0%
Liabilities 17.7M USD -21.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 130K USD
Retained Earnings (Accumulated Deficit) -519M USD -1.91%
Stockholders' Equity Attributable to Parent 243M USD +3.33%
Liabilities and Equity 261M USD +1.17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.3M USD -4.84%
Net Cash Provided by (Used in) Financing Activities 1.65M USD -98.6%
Net Cash Provided by (Used in) Investing Activities 38.1M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 54M shares -12.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 14.5M USD
Deferred Tax Assets, Valuation Allowance 51.8M USD -68.5%
Deferred Tax Assets, Gross 54.7M USD -67.3%
Depreciation 1.59M USD -26.7%
Payments to Acquire Property, Plant, and Equipment 28K USD -83.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -9.46M USD +90.2%
Property, Plant and Equipment, Gross 18.2M USD +1.01%
Operating Lease, Liability, Current 2.19M USD -0.27%
Deferred Tax Assets, Operating Loss Carryforwards 1.44M USD -98.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.9M USD +17.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%